$3,160,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.7391, CHC Drug Pricing Protection Act H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry"
You can find more data on corporate lobbying on Quiver Quantitative.
BMY Congressional Stock Trading
Members of Congress have traded $BMY stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:
- REPRESENTATIVE MIKE KELLY sold up to $50,000 on 05/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
BMY Insider Trading Activity
BMY insiders have traded $BMY stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:
- DAVID V ELKINS (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $1,850,016.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BMY Hedge Fund Activity
We have seen 1,145 institutional investors add shares of BMY stock to their portfolio, and 999 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 17,527,686 shares (+116.4%) to their portfolio in Q1 2026, for an estimated $1,063,054,155
- CAPITAL INTERNATIONAL INVESTORS removed 12,559,082 shares (-59.8%) from their portfolio in Q1 2026, for an estimated $761,708,323
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 10,207,019 shares (-14.3%) from their portfolio in Q1 2026, for an estimated $619,055,702
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 8,317,781 shares (-48.4%) from their portfolio in Q1 2026, for an estimated $504,473,417
- MARSHALL WACE, LLP removed 7,154,432 shares (-66.0%) from their portfolio in Q1 2026, for an estimated $433,916,300
- TWO SIGMA INVESTMENTS, LP added 6,873,064 shares (+147.4%) to their portfolio in Q1 2026, for an estimated $416,851,331
- SG AMERICAS SECURITIES, LLC added 6,286,007 shares (+239.6%) to their portfolio in Q1 2026, for an estimated $381,246,324
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BMY Analyst Ratings
Wall Street analysts have issued reports on $BMY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 02/23/2026
To track analyst ratings and price targets for BMY, check out Quiver Quantitative's $BMY forecast page.
BMY Price Targets
Multiple analysts have issued price targets for $BMY recently. We have seen 10 analysts offer price targets for $BMY in the last 6 months, with a median target of $62.0.
Here are some recent targets:
- Carter Gould from Cantor Fitzgerald set a target price of $54.0 on 07/06/2026
- Tim Anderson from B of A Securities set a target price of $67.0 on 04/09/2026
- Seamus Fernandez from Guggenheim set a target price of $72.0 on 04/08/2026
- Rajesh Kumar from HSBC set a target price of $60.0 on 03/17/2026
- Trung Huynh from RBC Capital set a target price of $60.0 on 02/25/2026
- David Amsellem from Piper Sandler set a target price of $75.0 on 02/23/2026
- Emily Field from Barclays set a target price of $75.0 on 02/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
